A study presented at the American College of Cardiology's Annual Scientific Session found
that semaglutide, a medication used to treat type 2 diabetes, can improve functional status …

Background More women than men have heart failure with preserved ejection fraction
(HFpEF). Objectives The purpose of this study was to assess baseline characteristics and …

This analysis of the STEP-HFpEF trial investigated the efficacy and tolerability of
subcutaneous semaglutide in patients with obesity-related HFpEF. 529 patients with HFpEF …

People with overweight or obese have an increased risk of developing heart failure and
atrial fibrillation but treatment strategies for this group of patients remain not established …

Semaglutide 2.4 mg improved heart failure-related symptoms in patients with heart failure
with preserved ejection fraction (HFpEF) and obesity, according to findings from the STEP …

Background Many therapies for heart failure (HF) have shown differential impact across the
spectrum of left ventricular ejection fraction (LVEF). Objectives In this prespecified analysis …

STUDY AFTER STUDY HAS SHOWN that adopting a healthier lifestyle and losing weight
can improve the outcomes for individuals with medical conditions. But can a weight loss …

Background Obesity is associated with adverse cardiac remodeling and is a key driver for
the development and progression of heart failure (HF). Once-weekly semaglutide (2.4 mg) …

Background Semaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, has
shown promise in weight management and cardiovascular outcomes in other populations …

Semaglutide 2.4 mg Shows Benefit as Treatment for Heart Failure with Obesity News Media
Medical World NewsPodcastsShowsState Of Sciences - PresentationsVideosWebinars …